Ascendis Pharma A (ASND) Invested Capital (2016 - 2025)
Ascendis Pharma A (ASND) has disclosed Invested Capital for 10 consecutive years, with $825.3 million as the latest value for Q4 2025.
- Quarterly Invested Capital rose 2.85% to $825.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $825.3 million through Dec 2025, up 2.85% year-over-year, with the annual reading at $825.3 million for FY2025, 2.85% up from the prior year.
- Invested Capital hit $825.3 million in Q4 2025 for Ascendis Pharma A, up from $802.4 million in the prior quarter.
- In the past five years, Invested Capital ranged from a high of $1.1 billion in Q4 2021 to a low of $536.4 million in Q4 2023.
- Historically, Invested Capital has averaged $816.5 million across 5 years, with a median of $802.4 million in 2024.
- Biggest five-year swings in Invested Capital: plummeted 31.87% in 2023 and later surged 49.59% in 2024.
- Year by year, Invested Capital stood at $1.1 billion in 2021, then plummeted by 30.38% to $787.4 million in 2022, then tumbled by 31.87% to $536.4 million in 2023, then surged by 49.59% to $802.4 million in 2024, then increased by 2.85% to $825.3 million in 2025.
- Business Quant data shows Invested Capital for ASND at $825.3 million in Q4 2025, $802.4 million in Q4 2024, and $536.4 million in Q4 2023.